Wilson Sonsini Goodrich & & Rosati’s 2021 Innovation and Life Sciences IPO Report presents analysis related to 179 initial public offerings and 6 direct listings finished by U.S.-based technology and life sciences business between January 1 and December 31, 2021. Except where noted, the report analyzes both IPOs and direct listings and state quantitative and qualitative outcomes worrying filing, prices (for IPOs), and value stats; governance information; ownership and structure aspects; and defensive measures. The report also goes over concurrent private placements and signs of interest (for IPOs).
The first half of 2021 proved to be the most active first half of any year for tech and life sciences IPOs since the high levels reached during the dot-com period in the late 1990s. The 2nd half of 2021, while not as active, still caused a significantly high variety of IPOs. Meanwhile, there were six direct listings finished in 2021, a boost over two direct listings in 2020, and all six were by business in the technology sector.
Click here to read the report.